Westminster Health Forum policy conference:

Next steps for clinical trials and research in the UK

Timing: Morning, Tuesday, 27th January 2026

Taking place online

Draft agenda subject to change

8.30 Registration

9.00 Chair's opening remarks

Dr Scott Arthur MP

9.05 Assessing current issues in clinical research design and delivery, and opportunities for growth

Senior commentator

Questions and comments from the floor

9.30 Updated UK clinical trial regulations and priorities for practical implementation

Dr Kingyin Lee, Head, Clinical Trials, Medicines and Healthcare Products Regulatory Agency

Senior speaker confirmed from Health Research Authority

Questions and comments from the floor

10.05 Implementation of updated clinical trial regulations and strategies for increasing public engagement

updated UK Clinical Trial Regulations | responsibilities for safety and monitoring | delivering trials in primary care and community settings | role of ICBs in supporting clinical trials | recruitment and accessibility | digital inclusion and reducing barriers to participation, including geographic disparities | use of the NHS App | data governance | tackling underrepresentation | use of Inclusion and Diversity Plans | trial design flexibility for rare diseases | pathways for highly personalised medicines | public messaging, confidence, and trust

Toni Mathieson, CEO, Niemann-Pick UK

Dr Philippa Brice, Associate Director, Research and Impact, NHS Cambridgeshire and Peterborough ICS

Professor Pamela Kearns, Chair, IMPACCT (Initiative for Multi-stakeholder Partnership to Accelerate Children's Cancer Trials); and Emeritus Professor, Clinical Paediatric Oncology, University of Birmingham

Senior representative, industry

Senior representative, data

Questions and comments from the floor

11.00 Chair's closing remarks

Dr Scott Arthur MP

11.05 Break

11.15 Chair's opening remarks

Senior Parliamentarian

11.20 'What should the priorities of the Health Data Research Service be to transform clinical trials and research in the UK?'

Professor Cathie Sudlow, Review Lead, *Uniting the UK's Health Data: A Huge Opportunity for Society*; Director, Usher Institute and Head of School of Population Health Sciences, University of Edinburgh

Questions and comments from the floor

11.45 <u>Streamlining clinical trial delivery - key considerations for innovative technology, funding, the workforce, and data</u> frameworks

150-day target practicalities | impact of the Combined Review | sponsor confidence | Health Data Research Service and public trust | interoperability across NHS datasets | potential use of AI to support trial design and conduct | workforce recruitment and retention | joint NHS-university roles | new delivery centres and regional research hubs | UK attractiveness for global partnerships | wearable technology and real-time data collection | data quality and coding standards | funding for research infrastructure | expanding both commercial and non-commercial trial capacity | immigration, visas, and international recruitment | regional consistency in career pathways and roles

Taly Dvorkis, Director, Fieldfisher

Stuart Young, CEO, Panthera Biopartners

Professor Terry Jones, Director, Liverpool Head and Neck Centre; Director, Research, LUHFT and Cheshire and Merseyside ICS; and Director, NIHR Cheshire and Merseyside CRDC

Senior representative, industry

Senior representative, investment

Questions and comments from the floor

12.30 Next steps for clinical trials and research policy in the UK

Dr Louise Newport, Head, Clinical Trials Engagement and Governance, Department of Health and Social Care Questions and comments from the floor

12.55 Chair's and Westminster Health Forum closing remarks

Senior Parliamentarian

Jessica Lear, Westminster Health Forum

